How does 6976's PB Ratio compare to its peers?

6976 is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (6x).

How does 6976's PB Ratio compare vs other companies in the TW Biotechs Industry?

6976 is good value based on its Price-To-Book Ratio (1.6x) compared to the TW Biotechs industry average (3.9x).

What is 6976's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 6976's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 6976 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 6976's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Acepodia (TPEX:6976) - Stock Price, News & Analysis

6976 Stock Overview

Operates as a clinical stage biotechnology company. More details

6976 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 3% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (NT$17M)

Acepodia, Inc. Competitors

Tanvex BioPharma

TWSE:6541

NT$11.2b

Adimmune

TWSE:4142

NT$9.4b

Mycenax Biotech

TPEX:4726

NT$9.3b

TaiGen Biopharmaceuticals Holdings

TPEX:4157

NT$9.0b

Price History & Performance

Summary of all time highs, changes and price drops for Acepodia
Historical stock prices
Current Share Price	NT$18.05
52 Week High	NT$36.40
52 Week Low	NT$17.00
Beta	0
11 Month Change	-12.80%
3 Month Change	-24.63%
1 Year Change	-43.15%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-55.43%

Recent updates

Shareholder Returns

	6976	TW Biotechs	TW Market
7D	1.4%	-1.0%	0.8%
1Y	-43.1%	0.7%	30.3%

Return vs Industry: 6976 underperformed the TW Biotechs industry which returned 0.7% over the past year.

Return vs Market: 6976 underperformed the TW Market which returned 30.3% over the past year.

Price Volatility

Is 6976's price volatile compared to industry and market?
6976 volatility
6976 Average Weekly Movement	5.2%
Biotechs Industry Average Movement	4.4%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.0%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6976 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6976's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Sonny Hsiao	www.acepodia.com

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address gaps in cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies.

Acepodia, Inc. Fundamentals Summary

How do Acepodia's earnings and revenue compare to its market cap?
6976 fundamental statistics
Market cap	NT$10.32b
Earnings (TTM)	-NT$379.78m
Revenue (TTM)	NT$16.90m

610.4x

P/S Ratio

-27.2x

P/E Ratio

Is 6976 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6976 income statement (TTM)
Revenue	NT$16.90m
Cost of Revenue	NT$96.00k
Gross Profit	NT$16.81m
Other Expenses	NT$396.59m
Earnings	-NT$379.78m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.66
Gross Margin	99.43%
Net Profit Margin	-2,246.70%
Debt/Equity Ratio	0%

How did 6976 perform over the long term?

See historical performance and comparison

Acepodia TPEX:6976 Stock Report